Citadel Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.65M | Sell |
258,278
-372,664
| -59% | -$7.75M | ﹤0.01% | 4511 |
|
|
2026
Q1 | $14.7M | Buy |
630,942
+446,939
| +243% | +$9.7M | ﹤0.01% | 2707 |
|
|
2025
Q4 | $3.87M | Sell |
184,003
-362,265
| -66% | -$6.32M | ﹤0.01% | 4724 |
|
|
2025
Q3 | $8.4M | Sell |
546,268
-93,732
| -15% | -$1.23M | ﹤0.01% | 3518 |
|
|
2025
Q2 | $5.99M | Sell |
640,000
-2,274,882
| -78% | -$25M | ﹤0.01% | 3807 |
|
|
2025
Q1 | $35.8M | Buy |
2,914,882
+1,825,079
| +167% | +$25.7M | 0.01% | 1438 |
|
|
2024
Q4 | $14.4M | Buy |
1,089,803
+1,055,783
| +3,103% | +$18.1M | ﹤0.01% | 2541 |
|
|
2024
Q3 | $655K | Sell |
34,020
-155,961
| -82% | -$3.22M | ﹤0.01% | 7691 |
|
|
2024
Q2 | $3.9M | Buy |
189,981
+156,172
| +462% | +$3.27M | ﹤0.01% | 4146 |
|
|
2024
Q1 | $805K | Sell |
33,809
-209,176
| -86% | -$4.67M | ﹤0.01% | 7380 |
|
|
2023
Q4 | $5.25M | Sell |
242,985
-192,508
| -44% | -$2.96M | ﹤0.01% | 3709 |
|
|
2023
Q3 | $6.32M | Buy |
435,493
+198,543
| +84% | +$3.76M | ﹤0.01% | 3300 |
|
|
2023
Q2 | $4.96M | Sell |
236,950
-1,342,719
| -85% | -$28M | ﹤0.01% | 3670 |
|
|
2023
Q1 | $33.4M | Sell |
1,579,669
-48,184
| -3% | -$1.2M | 0.01% | 1437 |
|
|
2022
Q4 | $41.4M | Buy |
1,627,853
+261,082
| +19% | +$6.09M | 0.01% | 1274 |
|
|
2022
Q3 | $32.8M | Sell |
1,366,771
-362,281
| -21% | -$8.13M | 0.01% | 1393 |
|
|
2022
Q2 | $33.3M | Sell |
1,729,052
-96,388
| -5% | -$1.61M | 0.01% | 1392 |
|
|
2022
Q1 | $31.7M | Sell |
1,825,440
-193,387
| -10% | -$3.26M | 0.01% | 1490 |
|
|
2021
Q4 | $44.2M | Buy |
2,018,827
+175,470
| +10% | +$3.24M | 0.01% | 1268 |
|
|
2021
Q3 | $35.2M | Sell |
1,843,357
-115,274
| -6% | -$1.92M | 0.01% | 1423 |
|
|
2021
Q2 | $33.6M | Sell |
1,958,631
-271,492
| -12% | -$4.97M | 0.01% | 1496 |
|
|
2021
Q1 | $49.9M | Buy |
2,230,123
+118,605
| +6% | +$2.68M | 0.01% | 1044 |
|
|
2020
Q4 | $47M | Buy |
2,111,518
+1,549,104
| +275% | +$32.1M | 0.01% | 991 |
|
|
2020
Q3 | $8.3M | Sell |
562,414
-479,166
| -46% | -$7.3M | ﹤0.01% | 2511 |
|
|
2020
Q2 | $15.4M | Buy |
1,041,580
+1,028,435
| +7,824% | +$15.7M | 0.01% | 1744 |
|
|
2020
Q1 | $144K | Sell |
13,145
-9,053
| -41% | -$85K | ﹤0.01% | 8337 |
|
|
2019
Q4 | $195K | Buy |
+22,198
| New | +$163K | ﹤0.01% | 8213 |
|
|
2019
Q1 | – | Sell |
-35,007
| Closed | -$200K | – | 9828 |
|
|
2018
Q4 | $156K | Sell |
35,007
-23,048
| -40% | -$126K | ﹤0.01% | 8034 |
|
|
2018
Q3 | $469K | Buy |
58,055
+35,557
| +158% | +$253K | ﹤0.01% | 6804 |
|
|
2018
Q2 | $158K | Buy |
+22,498
| New | +$221K | ﹤0.01% | 8036 |
|
Other funds holding SNDX
KCM
Citadel Advisors's SNDX Position: Q2 2026 in Review
Citadel Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 59% in Q2 2026, selling an estimated $7.75M and leaving 258,278 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #4511.
Citadel Advisors first reported a position in SNDX in Q2 2018 and has held it in 30 quarters since. The position peaked at $49.9M in Q1 2021. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- Citadel Advisors held 258,278 shares of Syndax Pharmaceuticals worth $5.65M as of Q2 2026.
- Citadel Advisors sold 372,664 Syndax Pharmaceuticals shares in Q2 2026, an estimated $7.75M.
- Syndax Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4511 holding.
- Citadel Advisors first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
- Citadel Advisors's Syndax Pharmaceuticals position peaked at $49.9M in Q1 2021.
- 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.